Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells.

Mol Ther Methods Clin Dev · 2017 · PMC5415320 · PMID 28480307

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

Because of the one mouse that failed to respond to the tolerogenic therapy, the differences in average antibody formation (856 versus 3,931 ng IgG1/mL and 2 versus 3.4 BU/mL) failed to reach statistical significance.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.